drugset

drugset / Trial / NCT00701636

Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery

NCT00701636 ↗

Phase 3 Completed 30 enrolled Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · collab Hartford Hospital · collab Western University of Health Sciences · collab

Non-randomizedSingle-groupOpen-labelPrevention

Summary

This investigation is a prospective, open-label pharmacokinetic study of daptomycin prophylaxis in patients undergoing coronary artery bypass graft surgery without valvular replacement.

Timeline

Start: 2008-07
Primary completion: 2010-10
Completion: 2010-10

Publications

Results Nguyen MH, Eells SJ, Tan J, Sheth CT, Omari B, Flores M, Wang J, Miller LG. Prospective, open-label investigation of the pharmacokinetics of daptomycin during cardiopulmonary bypass surgery. Antimicrob Agents Chemother. 2011 Jun;55(6):2499-505. doi: 10.1128/AAC.01404-10. Epub 2011 Mar 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Daptomycin	Other / unclassified	8 mg/kg	Intravenous

Indications